- Home
- GPRE vs BCAX Comparison
GPRE vs BCAX Comparison
Compare GPRE & BCAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GPRE
- BCAX
- Stock Information
- Founded
- GPRE 2004
- BCAX 2018
- Country
- GPRE United States
- BCAX United States
- Employees
- GPRE N/A
- BCAX N/A
- Industry
- GPRE Major Chemicals
- BCAX
- Sector
- GPRE Industrials
- BCAX
- Exchange
- GPRE Nasdaq
- BCAX NYSE
- Market Cap
- GPRE 542.8M
- BCAX 574.3M
- IPO Year
- GPRE N/A
- BCAX 2024
- Fundamental
- Price
- GPRE $7.88
- BCAX $10.53
- Analyst Decision
- GPRE Buy
- BCAX Strong Buy
- Analyst Count
- GPRE 7
- BCAX 7
- Target Price
- GPRE $10.42
- BCAX $29.17
- AVG Volume (30 Days)
- GPRE 1.4M
- BCAX 329.8K
- Earning Date
- GPRE 08-12-2025
- BCAX 08-16-2025
- Dividend Yield
- GPRE N/A
- BCAX N/A
- EPS Growth
- GPRE N/A
- BCAX N/A
- EPS
- GPRE N/A
- BCAX N/A
- Revenue
- GPRE $2,463,097,000.00
- BCAX N/A
- Revenue This Year
- GPRE $1.80
- BCAX N/A
- Revenue Next Year
- GPRE $2.92
- BCAX N/A
- P/E Ratio
- GPRE N/A
- BCAX N/A
- Revenue Growth
- GPRE N/A
- BCAX N/A
- 52 Week Low
- GPRE $3.14
- BCAX $7.80
- 52 Week High
- GPRE $17.84
- BCAX $28.09
- Technical
- Relative Strength Index (RSI)
- GPRE 58.03
- BCAX N/A
- Support Level
- GPRE $7.92
- BCAX N/A
- Resistance Level
- GPRE $8.75
- BCAX N/A
- Average True Range (ATR)
- GPRE 0.38
- BCAX 0.00
- MACD
- GPRE -0.10
- BCAX 0.00
- Stochastic Oscillator
- GPRE 27.50
- BCAX 0.00
About GPRE Green Plains Inc.
Green Plains Inc manufactures and sells ethanol and ethanol byproducts in two segments based on function. The ethanol production segment, which generates the majority of revenue, includes the production of ethanol, distillers grains, Ultra-High Protein and renewable corn oil. The agribusiness and energy services segment includes grain handling and storage, commodity marketing and merchant trading for company-produced and third-party ethanol, distillers grains, Ultra-High Protein, renewable corn oil, natural gas and other commodities.
About BCAX BICARA THERAPEUTICS INC
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.